Hologic (NASDAQ:HOLX) PT Raised to $90.00 at Mizuho

Hologic (NASDAQ:HOLX) had its target price raised by stock analysts at Mizuho from $85.00 to $90.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has an “outperform” rating on the medical equipment provider’s stock. Mizuho’s price objective indicates a potential upside of 12.16% from the company’s previous close.

Several other research firms have also issued reports on HOLX. Royal Bank of Canada reissued a “sector perform” rating and issued a $82.00 price target on shares of Hologic in a research report on Friday, August 16th. Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. Stephens reiterated an “overweight” rating and issued a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Tuesday, September 17th. Finally, StockNews.com downgraded Hologic from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 27th. Five analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Hologic has an average rating of “Moderate Buy” and an average price target of $87.27.

Hologic Trading Up 1.3 %

Shares of HOLX stock opened at $80.24 on Friday. Hologic has a 12-month low of $64.02 and a 12-month high of $84.67. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The company has a 50 day moving average of $81.28 and a 200-day moving average of $77.42. The firm has a market cap of $18.73 billion, a P/E ratio of 40.94, a PEG ratio of 2.58 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business’s revenue was up 2.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.93 earnings per share. Sell-side analysts anticipate that Hologic will post 4.09 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Benjamin Jordan Cohn sold 5,093 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the transaction, the insider now owns 10,476 shares of the company’s stock, valued at $858,927.24. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the transaction, the insider now directly owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the sale, the insider now directly owns 3,735 shares of the company’s stock, valued at $310,415.85. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,280 shares of company stock worth $1,469,973. Insiders own 1.75% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of HOLX. Innealta Capital LLC bought a new position in Hologic during the 2nd quarter worth approximately $25,000. iA Global Asset Management Inc. bought a new stake in Hologic during the 1st quarter valued at $37,000. Sunbelt Securities Inc. purchased a new stake in Hologic during the 2nd quarter valued at $37,000. Cranbrook Wealth Management LLC bought a new stake in Hologic in the 2nd quarter worth $47,000. Finally, Mather Group LLC. purchased a new position in shares of Hologic in the first quarter valued at about $48,000. 94.73% of the stock is owned by institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.